Use of imatinib mesylate in CML patients autografted in the pre-imatinib mesylate era: A single center experience.

被引：0
|
作者：
Liesveld, JL [1 ]
Nichols, D [1 ]
Ifthikharuddin, JJ [1 ]
Lancet, JE [1 ]
Abboud, CN [1 ]
机构：
[1] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5471
引用
收藏
页码：473B / 473B
页数：1
相关论文
共 50 条
  • [41] Higher dosing of imatinib mesylate achieved higher response rates in patients with newly diagnosed CML
    不详
    ONCOLOGY-NEW YORK, 2004, 18 (02): : 167 - 167
  • [42] Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience
    Breccia, Massimo
    Cannella, Laura
    Frustaci, Annamaria
    Stefanizzi, Caterina
    Levi, Anna
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2008, 32 (05) : 835 - 836
  • [43] Treatment and resistance to imatinib in CML patients: Experience of a Portuguese center
    Castro, I.
    Santo, A. Espirito
    Cameiro, A.
    Silva, M. J.
    Fernandes, A.
    Cancela, J.
    Principe, F.
    Ferreira, F.
    Lemos, R.
    Andrade, J.
    Costa, A.
    Trigo, F.
    Moreira, I.
    Costa, T.
    Silva, F.
    Guimaraes, J. E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 248 - 248
  • [44] Imatinib (Glivec®) in the treatment of patients with CML in accelerated phase -: Czech experience.
    Faber, E
    Hlusf, A
    Indrák, K
    Jarosová, M
    Holzerová, M
    Zapletalová, J
    Klamová, H
    Vítek, A
    Voglová, J
    Zák, P
    Brychtová, Y
    Cieslar, P
    Haber, J
    Slaby, J
    Sumná, E
    Vozobulová, V
    Kuncar, J
    Sisková, M
    Cmunt, E
    Heinzová, V
    Blazek, B
    BLOOD, 2002, 100 (11) : 319B - 319B
  • [45] Cytogenetic findings in imatinib mesylate-treated Philadelphia-positive chronic myelogenous leukemia patients: a single-center experience
    Mesanovic, Semir
    Peric, Milan
    Mustedanagic-Mujanovic, Jasminka
    Iljazovic, Ermina
    Cickusic, Elmir
    Eminovic, Izet
    CHROMOSOME RESEARCH, 2011, 19 : S142 - S143
  • [46] Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country
    Medhi, Kunjahari
    Raina, Vinod
    Kumar, Lalit
    Sharma, Atul
    Bakhshi, Sameer
    Gupta, Ritu
    Kumar, Rajive
    LEUKEMIA & LYMPHOMA, 2010, 51 (10) : 1850 - 1854
  • [47] Eribulin mesylate in Indian patients: A single center experience
    Thippeswamy, R.
    Patil, S.
    Shashidara, H. P.
    Satheesh, C. T.
    Vittal, H.
    Mishra, S.
    INDIAN JOURNAL OF CANCER, 2015, 52 (03) : 297 - U61
  • [48] Risk factors for myelosuppression in chronic phase CML patients treated with Imatinib mesylate (STI571).
    Mauro, MJ
    O'Dwyer, ME
    Kurilik, G
    Blasdel, C
    Farnsworth, M
    Fong, D
    Hsieh, YC
    Mori, M
    Ford, JM
    Druker, BJ
    BLOOD, 2001, 98 (11) : 139A - 139A
  • [49] Compliance with imatinib mesylate associated with lower health resource utilization and costs for patients with CML and GIST.
    Halpern, Rachel
    Barghout, Victoria
    Williams, Denise
    BLOOD, 2007, 110 (11) : 372B - 372B
  • [50] Conception and pregnancy in patients (pts) with chronic myeloid leukemia (CML) receiving therapy with imatinib mesylate (IM).
    Ault, P
    Kantarjian, H
    O'Brien, S
    Koller, C
    Faderl, S
    Freireich, EJ
    Rios, MB
    Cortes, J
    BLOOD, 2005, 106 (11) : 321A - 321A
12345